Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GlaxoSmithKline (GSK) Share Price & Analysis
407 Followers
GSK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,264.04p - 1,719.80p
Previous Close1,639.5p
Volume71.27K
Average Volume (3M)8.95M
Market Cap
£67.86B
Enterprise Value79.85B
Total Cash (Recent Filing)£5.18B
Total Debt (Recent Filing)£18.02B
Price to Earnings (P/E)13.5
Beta0.41
Next Earnings
May 01, 2024EPS Estimate
£0.37Next Dividend Ex-DateN/A
Dividend Yield3.63%
Share Statistics
EPS (TTM)1.22
Shares Outstanding4,117,033,438
10 Day Avg. Volume11,123,383
30 Day Avg. Volume8,947,384
Standard Deviation0.05
R-Squared0.29
Alpha0.00638
Financial Highlights & Ratios
Price to Book (P/B)-8.00
Price to Sales (P/S)242.10
Price to Cash Flow (P/CF)6.10
P/FCF Ratio7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,841.78pPrice Target Upside11.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
GlaxoSmithKline News
PremiumCompany Announcements
GSK’s Cancer Drug Nears Broader FDA Approval
PremiumCompany Announcements
GSK Executives Reinvest Dividends in Shares
PremiumCompany Announcements
GSK Executives Acquire Shares Post-Dividend
PremiumCompany Announcements
GSK’s Gepotidacin Shows Promise Against Gonorrhoea
PremiumCompany Announcements
GSK’s Shingrix Shows Decade-Long Shingles Protection
Bulls Say, Bears Say
Bulls Say
Financial GuidanceGSK's guidance to a margin of >31% by 2026 suggests stable future margins backed by strong product performance.
Product PerformanceSpecialty segment shows growth with strong performance from Ojjaara and Jemperli, aligning with expectations.
Stock RatingUpgrading GSK to BUY from NEUTRAL following key revenue updates and increased confidence in margin benefits, indicating attractive upside potential in the stock.
Bears Say
Legal RisksNegative risk-reward around Delaware given widespread expectation of win/settlement offers limited upside to shares whereas a decision to move to trial could see potential $7bn liability re-emerge and material downside.
Product PerformanceVaccines sales are below consensus with Arexvy underperforming expectations.
TaxationIncreased tax rate to 17% from 15.8% due to OECD pillar 2 implementation.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.29% Insiders
10.47% Mutual Funds
10.06% Other Institutional Investors
78.19% Public Companies and Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1264.04p and its highest was 1719.80p in the past 12 months.
What is GlaxoSmithKline’s market cap?
Currently, no data Available
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is May 01, 2024 which is in 3 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Jan 31, 2024. The company reported 0.289p earnings per share for the quarter, missing the consensus estimate of 0.29p by -0.001p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline does not currently pay dividends.
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is £0.37.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,144,880,000 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.289p in its last earnings report, missing expectations of 0.29p. Following the earnings report the stock price went up 1.964%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
1,841.78p (11.76% Upside)
1,841.78p (11.76% Upside)
Insider Transactions
Sold Shares
Worth £13.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.96%
12-Months-Change
Fundamentals
Return on Equity
41.16%
Trailing 12-Months
Asset Growth
-1.90%
Trailing 12-Months
Company Description
GlaxoSmithKline
In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.
---
GSK Stock 12 Months Forecast
Average Price Target
1,841.78p
▲(11.76% Upside)
Technical Analysis
Best Analysts Covering GSK
1 Year
1 Year Success Rate
24/32 ratings generated profit
1 Year Average Return
+6.83%
reiterated a buy rating 11 days ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +6.83% per trade.
---